Publications
View AllA randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
2 and 10 mg/kg Q3W, respectively, over control (P<0.00001 for both comparisons). The 6-month PFS rate was 34% (95% CI 27%-41%) and 38% (95% CI 31%45%) for pembrolizumab 2 and 10...
Chronic Myelogenous Leukemia, Version 1.2015
Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase)...
Affiliated Researchers
Institution Info
- Type
- healthcare
- Country
- N/A
- Publications
- 3
- Citations
- 1,693
External Links
Identifiers
- ROR
- https://ror.org/04vt65461